US Patent

US8324225 — Pyrrolopyrimidine compounds and their uses

Composition of Matter · Assigned to Novartis AG · Expires 2028-06-17 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects pyrrolopyrimidine compounds and their derivatives that inhibit protein kinases, useful in treating proliferative diseases.

USPTO Abstract

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.

Drugs covered by this patent

Patent Metadata

Patent number: US8324225
Jurisdiction: US
Classification: Composition of Matter
Expires: 2028-06-17
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.